Drug Pipeline Reviews
Drug Development Pipeline Reviews by Therapy Area
Douglas Insights tracks 758 drug candidates in clinical development across 6 therapy areas, 134 of them in Phase III, counted from 4,983 interventional trials and refreshed every 90 days.
Therapy areas
Which therapy areas does Douglas Insights cover?
Each therapy area has a free public page with the pipeline by phase, the leading sponsors and the next readouts, built from the same frozen dataset as the paid review.
Alzheimer's Disease drug pipeline
140 Alzheimer's disease candidates in clinical development from 100 sponsors, 18 readouts due in the next 12 months.
- Phase III: 18
- Phase II: 55
- Phase I: 67
- 754 trials
Atopic Dermatitis drug pipeline
133 atopic dermatitis candidates in clinical development from 88 sponsors, 35 readouts due in the next 12 months.
- Phase III: 25
- Phase II: 60
- Phase I: 48
- 663 trials
Chronic Kidney Disease drug pipeline
113 chronic kidney disease candidates in clinical development from 67 sponsors, 19 readouts due in the next 12 months.
- Phase III: 31
- Phase II: 41
- Phase I: 41
- 834 trials
Crohn's Disease drug pipeline
39 Crohn's disease candidates in clinical development from 32 sponsors, 11 readouts due in the next 12 months.
- Phase III: 4
- Phase II: 22
- Phase I: 13
- 398 trials
MASH drug pipeline
82 MASH candidates in clinical development from 56 sponsors, 12 readouts due in the next 12 months.
- Phase III: 13
- Phase II: 43
- Phase I: 26
- 507 trials
Obesity drug pipeline
251 obesity candidates in clinical development from 128 sponsors, 55 readouts due in the next 12 months.
- Phase III: 43
- Phase II: 72
- Phase I: 136
- 1,827 trials
| Therapy area | Candidates | Phase III | Sponsors | Trials | Data as of |
|---|---|---|---|---|---|
| Alzheimer's Disease | 140 | 18 | 100 | 754 | 3 Oct 2026 |
| Atopic Dermatitis | 133 | 25 | 88 | 663 | 3 Oct 2026 |
| Chronic Kidney Disease | 113 | 31 | 67 | 834 | 3 Oct 2026 |
| Crohn's Disease | 39 | 4 | 32 | 398 | 3 Oct 2026 |
| MASH | 82 | 13 | 56 | 507 | 3 Oct 2026 |
| Obesity | 251 | 43 | 128 | 1,827 | 3 Oct 2026 |
The paid review
What does a Douglas Insights pipeline review contain?
Each review is a 40–50 page report with an Excel tracker of every candidate, a 12–24 month catalyst calendar, a mechanism map with white space, and ranked calls on the candidates most likely to win.
01Executive summary and our call2–3 pp
The pipeline on one page and the desk's verdict on where treatment is heading.
- Pipeline size and phase mix
- The three calls that matter
- What changed since the last edition
02Disease and unmet need3 pp
Who is treated today, what current therapy leaves unmet, and how regulators judge new medicines.
- Patient population and diagnosis
- Treatment guidelines and gaps
- Regulatory endpoints
03Approved therapies3 pp
The marketed medicines every candidate will be measured against.
- Marketed medicines and their sponsors
- Post-approval trials
- The bar a new entrant must clear
04Pipeline at a glance4 pp
Every candidate counted by phase, drug type, sponsor and country.
- Assets by phase and drug type
- Sponsors by size of pipeline
- Trial footprint: US, Europe, China, Japan
05Mechanism landscape and white space5 pp
Which mechanisms are crowded and which no sponsor has entered.
- Mechanism classes and crowding
- Classes with no candidate yet
- Differentiation by route and dosing
06Key asset profiles12–15 pp
The leading 25 candidates, one profile each, every claim linked to a source document.
- Design and endpoints of the pivotal trials
- Data to date, with sources
- Next readout and the risk to it
07Catalyst calendar3 pp
Readouts, filings and regulatory decisions 24 months ahead.
- Readouts by quarter
- Filings and regulatory decisions
- Date confidence for each event
08Deals and partnering3 pp
Who is licensing, buying and partnering in the area, and on what terms.
- Licensing and M&A in the area
- Deal terms where disclosed
- Sponsors open to partnering
09Sponsor landscape3 pp
Large pharma against biotech, and how concentrated the pipeline is.
- Pipeline share by sponsor
- Sponsor-by-phase matrix
- New entrants since the last edition
10Our call: winners, risks, opportunities3–4 pp
The candidates most likely to win, ranked, with the reasoning and evidence.
- Ranked candidates
- Risks that could change the order
- Openings for new entrants and investors
11Methodology and source log2 pp
How the count is built and every document behind it.
- How candidates are counted and merged
- Every source document listed
- The ten quality checks
Ways to buy
| Option | What you get | Delivery | Price | |
|---|---|---|---|---|
| Pipeline Snapshot | This therapy area as published: PDF report + Excel tracker | Ready now | USD 3,000 | Enquire |
| Pipeline Review | Your indication, geography and phase cut-off; ranked calls and an analyst call | 2–3 weeks | From USD 4,000 | Enquire |
| Company Assessment | One sponsor's full pipeline against its peers | 2 weeks | From USD 5,000 | Enquire |
Method
How are the pipelines counted?
Every count starts from registered interventional trials on ClinicalTrials.gov. The same molecule under its code, generic and brand names is merged into one candidate, and each candidate is placed at the highest phase of its running or recent trials. Placebo, comparator and standard-of-care arms are never counted, and every merge is reviewed by the research desk.
Each edition is one frozen dataset that passes ten checks before release and is approved by the owner. See the research methodology.
Common questions
Drug pipeline reviews: frequently asked questions
How many drug candidates does Douglas Insights track?
758 candidates in clinical development across 6 therapy areas, 134 of them in Phase III, counted from 4,983 registered trials.
How often are the pipeline reviews updated?
90 days is the refresh cycle: every therapy area is re-harvested from the trial registry, re-checked and re-approved each quarter.
Can Douglas Insights build a review for my indication?
40–50 pages is the standard custom review: your indication, geography and phase cut-off, with ranked calls and an analyst call, delivered with the Excel tracker.
Need a pipeline we have not published?
Tell us the indication. Within one business day the Research Desk will scope a review: the trials in range, the candidates, and the delivery date.